DEEP RESEARCH · INBODY CORT
CORT Blood Pressure Monitor News and an Initial Revenue Check
A quick read on FDA status, KRW 72 million in revenue, and estimated early unit sales using a KRW 2.4 million unit-price assumption
0. Bottom line first
The CORT blood pressure monitor appears to have received FDA clearance as well. However, revenue is still around KRW 72 million, so using KRW 2.4 million per unit, I am at the stage of asking whether roughly 30 units have been sold. Given the comment that it needs to sell 1,000 units in Korea before spreading further, exports still seem some distance away.
1. FDA and product news
CORT also appears to have received FDA clearance. The CORT post referenced in the source is https://m.blog.naver.com/korot_/223660648854.
Official fact: The source post links to a related CORT blog post titled “CORT Co., Ltd. Attends the Korean Society of Hypertension Autumn International Conference.”
2. Translating early revenue into unit sales
KRW 72 million
The current revenue level mentioned in the source post.
KRW 2.4 million per unit
The unit-price assumption the author used to estimate sales volume.
About 30 units
A simple estimate from dividing KRW 72 million by KRW 2.4 million.
Revenue is still around KRW 72 million. If the price is KRW 2.4 million per unit, I wonder whether that means about 30 units have been sold.
Interpretation: Dividing KRW 72 million by KRW 2.4 million per unit gives about 30 units. This is the source author’s estimate, and actual unit sales would need separate confirmation.
3. Adoption and the distance to exports
However, considering the comment that 1,000 units need to be sold in Korea before it spreads afterward, exports seem somewhat far away.
Sources
- Source post: content/네이버블로그/2024-11-15-[인바디]코르트 혈압계 소식.md
- Naver Blog: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=223661995053
- CORT blog: https://m.blog.naver.com/korot_/223660648854